March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
March 2010 in “Ejc Supplements” CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.
23 citations
,
February 2014 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
March 2010 in “Ejc Supplements” Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.
19 citations
,
June 2018 in “Breast Cancer Research and Treatment” Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.
6 citations
,
November 2021 in “Oncology Research and Treatment” Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.
February 2024 in “BioMetals” Heavy metals like arsenic, cadmium, and lead can increase cancer risk and worsen outcomes.
12 citations
,
December 2010 in “Journal of thoracic oncology” New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
8 citations
,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
8 citations
,
November 2013 in “PLOS ONE” Cells with active Wnt signaling are less likely to turn into cancer when exposed to a cancer-causing gene.
May 2024 in “Journal of clinical medicine” Spironolactone is safe for treating female hair loss, but the safety of other drugs is uncertain.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
July 2008 in “Biomedical Imaging and Intervention Journal” New cancer treatments are more precise and less toxic, improving survival rates, but Asia faces challenges in adopting these advancements.
222 citations
,
January 2015 in “Annual Review of Pharmacology and Toxicology” Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.
28 citations
,
January 2017 in “Critical Reviews in Therapeutic Drug Carrier Systems” Nanomaterials in biomedicine can improve treatments but may have risks like toxicity, needing more safety research.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
3 citations
,
January 2024 in “Signal transduction and targeted therapy” Lymphatic vessels are essential for health and can be targeted to treat various diseases.
1 citations
,
April 2023 in “Biochemical and biophysical research communications” Keratin 79 is linked to liver damage and may help diagnose liver diseases.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
438 citations
,
October 2010 in “Oncogene” Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.
44 citations
,
December 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
18 citations
,
April 2011 in “International Journal of Molecular Medicine” Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
January 2020 in “Mastology” Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.
12 citations
,
February 2019 in “Journal of patient-reported outcomes” Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.